PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
13.50%
Net income growth of 13.50% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would note a slight edge that could grow if sustained.
-18.88%
D&A shrinks yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-78.05%
Working capital is shrinking yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
-146.04%
Inventory shrinks yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
-55.76%
Other WC usage shrinks yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
-1081.77%
Other non-cash items dropping yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-75.28%
Negative CFO growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-21.59%
CapEx declines yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-49.24%
We reduce “other investing” yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.
-26.52%
Reduced investing yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
12.45%
Debt repayment growth of 12.45% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.